ストックスクリーナーアプリを入手
18.48
0.11%
0.10
前日終値:
$18.38
開ける：
$18.41
24時間の取引高:
15,944
Relative Volume:
0.06
時価総額：
$1.00B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-17.30%
1か月 パフォーマンス:
-18.15%
6か月 パフォーマンス:
+0.00%
1年 パフォーマンス:
+0.00%
1日の値動き範囲:
$18.32
$18.83
1週間の範囲:
$17.62
$24.09
52週間の値動き範囲:
$17.62
$28.09
Bicara Therapeutics Inc Stock (BCAX) Company Profile
BCAX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
| BCAX | 18.48 | 1.00B | 0 | 0 | 0 | 0.00 |
| VRTX | 445.50 | 115.74B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 737.53 | 81.65B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 585.04 | 34.86B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 247.28 | 32.09B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 102.21 | 24.49B | 3.30B | -501.07M | 1.03B | 11.54 |
Bicara Therapeutics Inc (BCAX) 最新ニュース
First Turn Management LLC Takes $14.32 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX) - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Gap DownWhat's Next? - MarketBeat
FY2024 EPS Estimates for BCAX Cut by Cantor Fitzgerald - Defense World
FY2024 EPS Estimates for BCAX Reduced by Cantor Fitzgerald - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Shares Down 6.2%Here's Why - MarketBeat
Bicara Therapeutics Reports Strong IPO and Clinical Advancements - TipRanks
Bicara Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Bicara Therapeutics: Newly Minted Upsized IPO With Positive Early Data (NASDAQ:BCAX) - Seeking Alpha
Bicara Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - The Manila Times
Bicara's $362M IPO Success Powers Cancer Drug Trial with 64% Response Rate | BCAX Stock News - StockTitan
Bicara Therapeutics to Present at the Stifel 2024 Healthcare Conference - The Manila Times
Bicara Therapeutics (NASDAQ:BCAX) Rating Increased to Strong-Buy at RODMAN&RENSHAW - Defense World
Bicara Therapeutics Inc. (NASDAQ:BCAX) Receives $43.33 Consensus Target Price from Analysts - MarketBeat
Bicara Therapeutics (NASDAQ:BCAX) Upgraded to "Strong-Buy" at RODMAN&RENSHAW - MarketBeat
Bicara Therapeutics stock gets Buy rating from H.C. Wainwright on asset - Investing.com
Rodman & Renshaw Begins Coverage on Bicara Therapeutics (NASDAQ:BCAX) - MarketBeat
Biocon Stole Licensed Cancer Biotech to Fuel Spinoff, Suit Says - Bloomberg Law
Morgan Stanley spotlights 10 small-cap stocks with at least 50% upside - Kursiv Media
Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.9%Should You Buy? - MarketBeat
Balance Sheet Breakdown: Bicara Therapeutics Inc. (BCAX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
In the Green: Bicara Therapeutics Inc. (BCAX) Closes at 19.00, Up/Down -6.40 from Previous Day - The Dwinnex
Bicara Therapeutics (NASDAQ:BCAX) Hits New 52-Week LowWhat's Next? - MarketBeat
Down rounds don’t aid post-IPO performance - BioCentury
Bicara shares initiated with Buy on cancer drug potential By Investing.com - Investing.com South Africa
Bicara stock poised for growth with late-stage transition, Morgan Stanley optimistic - Investing.com
Bicara Therapeutics stock sees upside with lead drug potential, says Stifel - Investing.com
Bicara shares initiated with Buy on cancer drug potential - Investing.com India
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating - Investing.com
Cantor Fitzgerald starts Bicara Therapeutics with Overweight rating By Investing.com - Investing.com South Africa
Bicara Therapeutics stock sees upside with lead drug potential, says Stifel By Investing.com - Investing.com South Africa
Three startups aim to raise $400 mln as US biotech IPOs gain traction - Reuters
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - MSN
Market Update: Bicara Therapeutics Inc. (BCAX) Sees Negative Movement, Closing at 24.43 - The Dwinnex
Bicara Therapeutics, Adecoagro, and More Stocks See Action From Activist Investors - MSN
Kiran Mazumdar-Shaw’s niece makes debut at Nasdaq as Bicara Therapeutics goes public - The Financial Express
With IPO, have the capital and resources for clinical studies: Bicara CEO - The Economic Times
Bicara Therapeutics Rings the Opening Bell - Nasdaq
Bicara Therapeutics Rings the Nasdaq Stock Market Opening Bell - Nasdaq
Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN
TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc - GuruFocus.com
James E. Flynn Buys 70,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World
Upstream Bio goes public amid spate of IPOs - The Pharma Letter
Ra Capital Management, L.P. Purchases 1,833,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World
Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada
Ra capital executives buy Bicara Therapeutics shares for $32.99m - Investing.com India
FMR LLC Acquires New Stake in Bicara Therapeutics Inc - Yahoo Finance
Deerfield entities buy Bicara Therapeutics shares worth $1.26m By Investing.com - Investing.com Australia
Deerfield entities buy Bicara Therapeutics shares worth $1.26m - Investing.com
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Yahoo Finance
Bicara Therapeutics Inc (BCAX) 財務データ
Bicara Therapeutics Inc (BCAX) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
Bicara Therapeutics Inc (BCAX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Flynn James E | Possible Members of 10% Group |
Sep 17 '24 |
Buy |
18.00 |
70,000 |
1,260,000 |
897,587 |
0.42%
0.16%
大文字化:
|
ボリューム (24 時間):